---
input_text: Isoniazid therapy of Huntington disease. We describe clinical and biochemical
  changes in seven patients with Huntington disease given isoniazid (INH) in dosages
  three to five greater than normally used in tuberculosis. Because INH inhibits the
  enzyme gamma-aminobutyric acid aminotransferase (GABA-T), and increases GABA content
  in the brains of experimental animals, it might correct the brain GABA deficiency
  characteristic of Huntington disease. Of six patients treated long enough to be
  clinically evaluated, one showed marked and two others showed signifciant improvement.
  High-dose INH therapy carries serious toxic risks, which are influenced by patients'
  acetylator phenotypes. Nevertheless, results are sufficiently promising to warrant
  further controlled trials of INH or other GABA-T inhibitors in Huntington disease.
raw_completion_output: |-
  primary_disease: Huntington disease

  medical_actions: Isoniazid therapy; Increase GABA content; Controlled trials of INH or other GABA-T inhibitors

  symptoms: Brain GABA deficiency

  chemicals: Isoniazid (INH); gamma-aminobutyric acid (GABA)

  action_annotation_relationships: Isoniazid therapy TREATS Brain GABA deficiency IN Huntington disease; Increase GABA content (with gamma-aminobutyric acid) TREATS Brain GABA deficiency IN Huntington disease; Controlled trials of INH TREATS Huntington disease
prompt: |+
  Split the following piece of text into fields in the following format:

  subject_extension: <A chemical or drug mentioned in the relationship between the medical action and the symptom, for example, "analgesic agent therapy" has the aspect "analgesic">
  object_extension: <An optional term describing some specific aspect of the object, e.g. "analgesic agent therapy" has the aspect "analgesic">
  subject: <The medical action. For example: blood transfusion, radiation therapy, cardiac catheterization, pulse oximetry, otoscopy>
  predicate: <The relationship type between the medical action and the symptom, usually TREATS or PREVENTS.>
  object: <A sign or symptom associated with the disease and targeted by the medical action. For example, Low serum calcitriol, hypoplasia of the thymus, chronic cough, aortic stiffness, low pulse pressure>
  qualifier: <The primary disease the relationship is about, or specifically the disease the symptom is related to. For example, Beck-Fahrner syndrome, hereditary retinoblastoma, progeria, diabetes mellitus, infectious otitis media>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  Controlled trials of INH TREATS Huntington disease

  ===

extracted_object:
  primary_disease: MONDO:0007739
  medical_actions:
    - Isoniazid therapy
    - Increase GABA content
    - Controlled trials of INH or other GABA-T inhibitors
  symptoms:
    - Brain GABA deficiency
  chemicals:
    - CHEBI:6030
    - CHEBI:16865
  action_annotation_relationships:
    - subject: MAXO:0001298
      predicate: TREATS
      object: Brain GABA deficiency
      qualifier: MONDO:0007739
      subject_extension: CHEBI:6030
    - subject: Increase GABA content
      predicate: TREATS
      object: Brain GABA deficiency
      qualifier: MONDO:0007739
      subject_qualifier: with gamma-aminobutyric acid
      subject_extension: CHEBI:16865
    - subject: Controlled trials
      predicate: TREATS
      object: Huntington disease
      subject_extension: INH
named_entities:
  - id: MONDO:0007739
    label: Huntington disease
  - id: MAXO:0001298
    label: therapy
  - id: HP:0002180
    label: neurodegeneration
  - id: HP:0001268
    label: cognitive decline
  - id: HP:0100022
    label: movement disorders
  - id: HP:0002072
    label: choreic movements
  - id: MAXO:0009003
    label: preimplantation genetic testing
  - id: MAXO:0001592
    label: RNA interference therapy
  - id: HP:0000716
    label: depression
  - id: HP:0000739
    label: anxiety
  - id: HP:0000737
    label: irritability
  - id: CHEBI:7735
    label: olanzapine
  - id: MAXO:0000882
    label: behavioral interventions
  - id: HP:0004395
    label: malnutrition
  - id: MAXO:0000011
    label: physical therapy
  - id: CHEBI:22720
    label: benzodiazepines
  - id: CHEBI:2618
    label: amantadine
  - id: CHEBI:15765
    label: levodopa
  - id: HP:0002315
    label: Headache
  - id: CHEBI:134738
    label: Laquinimod
  - id: CHEBI:4903
    label: Ethinylestradiol
  - id: CHEBI:6443
    label: Levonorgestrel
  - id: HP:0001251
    label: Ataxia
  - id: HP:0001260
    label: Dysarthria
  - id: HP:0002119
    label: Ventricular dilatation
  - id: HP:0100543
    label: cognitive deficits
  - id: HP:0000708
    label: Behavioral changes
  - id: CHEBI:92976
    label: Latrepirdine
  - id: MONDO:0005559
    label: Neurodegenerative diseases
  - id: CHEBI:16243
    label: Quercetin
  - id: CHEBI:3962
    label: Curcumin
  - id: CHEBI:27881
    label: Resveratrol
  - id: CHEBI:75095
    label: Chrysin
  - id: CHEBI:28821
    label: Piperine
  - id: CHEBI:17620
    label: Ferulic acid
  - id: CHEBI:78330
    label: Huperzine A
  - id: CHEBI:16118
    label: Berberine
  - id: CHEBI:2979
    label: Baicalein
  - id: CHEBI:28230
    label: Hesperetin
  - id: CHEBI:26536
    label: Retinoic acid
  - id: MAXO:0000127
    label: Genetic testing
  - id: CHEBI:76004
    label: Dimethyl fumarate
  - id: MAXO:0010012
    label: coenzyme Q10 supplementation
  - id: HP:0003287
    label: mitochondrial dysfunction
  - id: HP:0025464
    label: oxidative stress
  - id: CHEBI:46245
    label: coenzyme Q10
  - id: CHEBI:31687
    label: idebenone
  - id: MONDO:0100339
    label: Friedreich ataxia
  - id: MONDO:0016621
    label: Juvenile Huntington Disease
  - id: MAXO:0000021
    label: Palliative care
  - id: CHEBI:6030
    label: Isoniazid (INH)
  - id: CHEBI:16865
    label: gamma-aminobutyric acid (GABA)
